Back to search
FDAFDA · Food and drugs·Recall number Z-1066-2018

Neoplastine® Cl Plus @ (ref.00374) Product Usage: Manual or automated determination of the prothrombin time (PT).

Published March 21, 2018 · Recall initiated: October 25, 2017

Summary

FDA records medical device Class II recall Z-1066-2018, published March 21, 2018 and initiated October 25, 2017. Recalling firm: Diagnostica Stago, Inc.; Status: Terminated; Reported quantity: 1636 Kits; Lot: Lot 115080 (Exp: 01-2018) Lot 251241 (Exp: 01-2018). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Diagnostica Stago, Inc.
Distributor
Nationally
Lot
Lot 115080 (Exp: 01-2018) Lot 251241 (Exp: 01-2018)
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Neoplastine® Cl Plus @ (ref.00374) Product Usage: Manual or automated determination of the prothrombin time (PT). recalled?

Yes. FDA published recall Z-1066-2018 on March 21, 2018. Reported hazard: Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

What should I do if I have this product?

Voluntary: Firm initiated · Letter